A Phase 3 interventional study of Dronabinol and Placebo in Knee Osteoarthritis, Knee Injuries and Meniscus Tear, sponsored by Northwestern University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Northwestern University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Osteoarthritis, Knee by Northwestern University — 3 open to participants now, 5 under way, 1 of them phase 3. Osteoarthritis, Knee · Northwestern University.
Among the 12 studies in Osteoarthritis, Knee by Northwestern University, this one is the 8th largest by planned enrollment, is one of 2 that started in 2022, is the only one in phase 3, and was the 7th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →3 of the 12 studies in Osteoarthritis, Knee by Northwestern University are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 40–80
Northwestern University · Sites in United States
Ages 21–79
Northwestern University · Sites in United States
Ages 41+
By country, each count listing its studies:
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 50 across the 12 interventional studies. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
1 of the studies in Osteoarthritis, Knee by Northwestern University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05430230Northwestern UniversityStudy of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Osteoarthritis, Knee by Northwestern University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the proposed study is to evaluate the efficacy of dronabinol for postoperative pain after arthroscopic surgery of the knee. The investigators hypothesize that dronabinol will relieve pain, reduce opioid consumption and will result in few negative side effects. If this pilot study shows promising results the investigators will expand the trial to include additional arthroscopic surgeries (hip, shoulder) and other types of orthopaedic surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient who will undergo arthroscopic surgery of the knee including, but not limited to,
Exclusion Criteria:
Patients taking any of the following drugs or supplements
Medication restrictions
Patients will received dronabinol (5mg) twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
Drug: Dronabinol
Patients will received placebo twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
Drug: Placebo
5mg 2x daily for 7 days
Also known as: Marinol
1 caplet 2x daily for 7 days
Opioid consumption
Count of number of hydrocodone/acetaminophen tablet consumed
Time frame: up to 7 days post-surgery
Pain Visual Analog Scale (VAS)
Scored from 0 (no pain) to 10 (worst possible pain)
Time frame: up to 7 days post-surgery
Patient-Reported Outcomes Measurement Information System (PROMIS) Bank v1.1 - Pain Interference
PROMIS measures generate T-scores. T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population (usually U.S. general population). A low score indicates less pain interference (better outcome) and a high score indicates more pain interference (worse outcome).
Time frame: up to 21 days post-surgery
PROMIS Bank v2.0 - Pain Behavior
PROMIS measures generate T-scores. T-scores are standard scores with a mean of 50. A low score indicates less pain (better outcome) and a high score indicates more pain (worse outcome).
Time frame: up to 21 days post-surgery
PROMIS Bank v2.0 - Physical Function
PROMIS measures generate T-scores. T-scores are standard scores with a mean of 50. A low score indicates worse physical functioning and a high score indicates better physical functioning.
Time frame: up to 21 days post-surgery
Started Jun 2022 (actual). Primary completion is estimated for Dec 2027, 66 months after the start.
Of 36 non-industry phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 66 months is above that.
Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Dec 2026 → Dec 2027 and completion Jun 2027 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronabinol